Chargement

Slzii.com Recherche

Recherche (Nouvelles)

Pierre Fabre Pharmaceuticals Resubmits Tabelecleucel Biologics License Application For Treatment Of Epstein-Barr Virus Positive-Post-Transplant Lymphoproliferative Disease To The FDA

Pierre Fabre Pharmaceuticals Resubmits Tabelecleucel Biologics License Application For Treatment Of Epstein-Barr Virus Positive-Post-Transplant Lymphoproliferative Disease To The FDA
Menafn english health top

(MENAFN - PR Newswire) If approved, tabelecleucel will be the first FDA-authorized treatment for relapsed/refractory EBV+ PTLD patients whose survival is measured in only a few weeks to months ...
2026-09-30 08:07:48

Que fais-tu?
0.020648956298828


Nouvelles
Menafn

Dernières nouvelles et titres
(MENAFN - PR Newswire) If approved, tabelecleucel will be the first FDA-authorized treatment for relapsed/refractory EBV+ PTLD patients whos...
Nouvelles